Comprehensive Analysis of Differential Gene Expression and Correlated Immune Infiltration in Bladder Cancer

Xiao  Xiao; Junxiong  Peng; Yong  Chen; Xingshan Lu; Wei Sun; Weizhong Xiao; Mengjuan Yuan; Xiaolan Huang

doi:10.18502/ijph.v52i6.12988

Xiao Xiao Urology Department, Chongqing University Fuling Hospital, Chongqing, 408000, PR China
Junxiong Peng Urology Department, Chongqing University Fuling Hospital, Chongqing, 408000, PR China
Yong Chen Urology Department, Chongqing University Fuling Hospital, Chongqing, 408000, PR China
Xingshan Lu Urology Department, Chongqing University Fuling Hospital, Chongqing, 408000, PR China
Wei Sun Urology Department, Chongqing University Fuling Hospital, Chongqing, 408000, PR China
Weizhong Xiao Urology Department, Chongqing University Fuling Hospital, Chongqing, 408000, PR China
Mengjuan Yuan Urology Department, Chongqing University Fuling Hospital, Chongqing, 408000, PR China
Xiaolan Huang Urology Department, Chongqing University Fuling Hospital, Chongqing, 408000, PR China

DOI: https://doi.org/10.18502/ijph.v52i6.12988

Keywords: Bladder cancer; Differentially expressed genes (DEGs); Network analysis; Biomarker; Immune infiltration

Abstract

Background: Bladder cancer (BCa) is one of the most common urinary tract malignancies. Our study aimed to provide promising biomarkers for BCa screening and prognosis.

Methods: BCa samples were obtained from Gene Expression Omnibus (GEO) datasets. Differentially expressed genes (DEGs) were analysed by GO/KEGG analysis. Univariate Cox hazard analysis and Kaplan Meier Curve clarified the relevance of DEGs and survival. Receiver operating characteristic (ROC) curve showed the discrimination ability of DEGs in BCa patient outcome prediction. RT-PCR was used to validate gene expression.

Results: Overall, 61 common up regulated and 170 common down-regulated genes in BCa were obtained. DEGs were mainly enriched in proliferation and metastasis processes. CDC20, COL14A1, SPARCL1, TMOD1, RHOJ, FXYD6 and MFAP4 had clinical relevance to survival with high accuracy. CDC20, SPARCL1 and TMOD1 are promising biomarkers of BCa. CDC20, SPARCL1 and TMOD1 are involved in cancer immune infiltration.

Conclusion: CDC20, SPARCL1 and TMOD1 are promising biomarkers of bladder cancer. In addition, CDC20, SPARCL1 and TMOD1 are involved in cancer immune infiltration, which provides new targets in immune therapy in bladder cancer.